• Recent emerging shifts in practice are expected to dramatically change treatment patterns for chronic myeloid leukemia in chronic phase (CML-CP): -The 2013 European LeukemiaNet (ELN) guidelines recommend switching to a second-line tyrosine kinase inhibitor (TKI) therapy as early as 6 months for patients who fail to achieve an adequate molecular response (MR; BCR-ABL1 ≤ 10%) with a first-line TKI 1 -These guidelines also recognize the possibility of treatment-free remission (TFR) for patients with deep MR, with newer guidelines from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) stating that select patients with deep MR may attempt treatment discontinuation. [2] [3] • Nilotinib and dasatinib are second-generation TKIs indicated for the treatment of newly diagnosed CML-CP and in patients with CML-CP who are intolerant or resistant to imatinib • There are no head-to-head clinical trials comparing nilotinib with dasatinib; however, there is real-world evidence to suggest that second-line nilotinib may provide better health outcomes than dasatinib (such as improved progression-free and overall survival rates) 4 • Given the several TKIs available to treat CML-CP and the changing CML-CP treatment landscape, payers are interested in the cost and health outcome benefits of second-line nilotinib compared with dasatinib
OBJECTIVE
• To examine the cost-effectiveness of nilotinib compared with dasatinib in the second-line setting in Russia, considering treatment recommendations from the ELN guidelines
METHODS
• A partitioned survival model was developed ( (BCR-ABL1 ≤ 10% and ≤ 0.01%, respectively) over time were not reported in the chart review and instead were estimated based on published clinical trials [5] [6] • Patients with sustained MR 4 were eligible for TFR, with ≈ 50% maintaining TFR beyond 12 months -MR 4 was used as the molecular response threshold for TFR eligibility to reflect clinical practice in Russia at the time of the analysis -Sustained TFR at MR 4 was modeled from the DADI trial, a dasatinib TFR study 7 • All drug and health state costs were specific to Russia [8] [9] -Health state resource use included physician visits and molecular monitoring • Discounting at 5% of costs and effects was used, in accordance with the pharmacoeconomic guidelines for Russia 10 • Disutilities were applied to each CML health state; values were derived from a published time-trade-off preference survey conducted among patients with CML Assumed to be the same as the "Second-line TKI" health state.
RESULTS
• Due to improved MR, PFS, and OS, the benefits of nilotinib translated into the following ( Table 2) 
DISCUSSION
• Results were driven by estimates of TOT, PFS, and OS from a medical chart review, which represented the best available data for comparative effectiveness of nilotinib vs dasatinib • A primary limitation of the study was the lack of head-to-head trials of nilotinib and dasatinib or trials with similar designs that could have been used to conduct an adjusted indirect comparison (such as a network metaanalysis) • A strength of this economic study was that it considered emerging treatment patterns based on the 2013 ELN guidelines and included the ability of patients to enter TFR
